Fundraising Fox

Tellus Therapeutics

Hillsborough, US · Founded 2018 · Delaware corporation

Tellus Therapeutics is a biopharmaceutical company developing therapeutics. The about page primarily details the background of its board chairman.

Founders & leadership

JE
Jason E. KarlicNamed on SEC filing
AM
Alex M. RuckdaeschelNamed on SEC filing
EJ
Eric J. BennerNamed on SEC filing

Board

CG
Chris GarabedianChairman of the Board

Reported raises · per SEC filings

Form D private placements

$18.1M disclosed across 3 rounds · 2019–2022

$16MraisedFeb 2023 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Chris GarabedianDirector
  • Jason E. KralicExecutive Officer, Director
  • Eric J. BennerExecutive Officer, Director
  • Fred CalloriDirector
Offering amount
$35M
Amount sold
$16M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2MraisedJul 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric J. BennerExecutive Officer, Director
  • Jason E. KralicExecutive Officer, Director
  • Fred CalloriDirector
  • Chris GarabedianDirector
Offering amount
$2M
Amount sold
$2M
First sale
May 2021
Incorporated
Corporation, North Carolina, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$75KraisedJan 2019 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jason E. KarlicExecutive Officer, Director
  • Alex M. RuckdaeschelDirector
  • Eric J. BennerExecutive Officer, Director
Offering amount
$75K
Amount sold
$75K
First sale
Jan 2019
Incorporated
Corporation, North Carolina, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Talus Bio14 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Trisaluslifesci12 shared keywordsTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Totus Medicines10 shared keywordsTotus Medicines is a biopharmaceutical company developing small molecule drugs to address untreatable diseases by combining approaches in molecular design, structural biology, genetics, and cell biology. The company focuses on oncology and other therapeutic areas for patients with currently incurable conditions.
Amicus Therapeutics10 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Stylus Medicine9 shared keywordsStylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.

Companies competing with Tellus Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Tellus Therapeutics do?
Tellus Therapeutics is a biopharmaceutical company developing therapeutics. The about page primarily details the background of its board chairman.
How much funding has Tellus Therapeutics raised?
Tellus Therapeutics has disclosed $18.1M raised across 3 rounds.
Where is Tellus Therapeutics headquartered?
Tellus Therapeutics is headquartered in Hillsborough, US.